Bayer

European Medicines Agency confirms asundexian marketing authorization application for assessment in secondary prevention of ischemic stroke

10 Jun 2026

Finerenone significantly reduced the risk of kidney disease progression and cardiovascular outcomes in broad patient populations with CKD

05 Jun 2026

Bayer’s finerenone significantly reduced kidney function decline and a composite of cardiovascular-kidney outcomes versus placebo in patients with non-diabetic chronic kidney disease

05 Jun 2026

Kerendia™ approved in China for new indication in adult patients with heart failure with LVEF ≥40%

22 May 2026

U.S. FDA grants Priority Review for finerenone in chronic kidney disease associated with type 1 diabetes

21 May 2026

New drug applications for Bayer’s FXIa inhibitor accepted by U.S. Food and Drug Administration under Priority Review and by Japan’s Ministry of Health, Labour and Welfare

19 May 2026

FDA grants sevabertinib Priority Review as a first-line treatment for patients with HER2-mutant non-small cell lung cancer

18 May 2026

Bayer AG First Quarter 2026 Results and Media Update

12 May 2026

Bayer reports solid start to the year and confirms currency-adjusted Group guidance for 2026

12 May 2026

AskBio Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting

08 May 2026

View details about the software product Informachine News Trackers